Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (1809)	12/11/2007 7:20:48 PM
From: tuck	Read Replies (1) \| Respond to of 1826

>>MGI Pharm-Eisai Deal Has $129M Break-Up Fee >MOGN Last update: 12/11/2007 5:51:53 PM DOW JONES NEWSWIRES MGI Pharma Inc. (MOGN) could owe a $129 million break-up fee to Eisai Co. Ltd. (ESALY) if the Japanese company's agreement to buy MGI Pharma isn't completed, according to a regulatory filing Tuesday. Eisai, a drug maker with a specialty in cancer treatments, agreed to buy MGI Pharma for $3.9 billion in cash, or $41 a share. MGI Pharma may have to pay the fee if, among other possible scenarios, it ends the merger agreement and accepts another acquisition proposal that it believes is superior to Eisai's, according to a filing with the Securities and Exchange Commission. Bloomington, Minn.-based MGI Pharma is a biopharmaceutical company focused on cancer treatments. Its shares closed Tuesday at $40.01, up 1 cent. -Antonie Boessenkool, Dow Jones Newswires; 202-862-7139<< Cheers, Tuck